drugset / Trial / NCT04152577
R2 and Combination Chemotherapy Versus R and Combination Chemotherapy in Newly Diagnosed Highly Aggressive B-NHL
RandomizedParallel-groupSingle-blindTreatment
Summary
In this study，lenalidomide was added in the first-line treatment in the newly diagnosed highly invasively non-Hodgkin B-cell lymphoma. The R2-CHOP/R2-EPOCH etc was applied compared with the classical R-CHOP/R-EPOCH etc. The investigators tried to explore a more effective and safe treatment regimen for patients with high-risk B-cell lymphoma to improve the patient's poor prognosis.
Timeline
- Start
- 2019-06-05
- Primary completion
- 2021-10-01
- Completion
- 2022-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | 25 mg | Oral |
| Background | Cyclophosphamide | Other / unclassified | 750 mg/m2 | — |
| Background | Doxorubicin | Other / unclassified | 30 mg/m2 | — |
| Background | Doxorubicin | Other / unclassified | 40 mg/m2 | — |
| Background | Doxorubicin | Other / unclassified | 70 mg/m2 | — |
| Background | Epirubicin | Small molecule | 15 mg/m2 | — |
| Background | Etoposide | Small molecule | 50 mg/m2 | — |
| Background | MTX | Unknown | 3.5 g | — |
| Background | Prednisone | Other / unclassified | 60 mg/m2 | — |
| Background | Prednisone | Other / unclassified | 100 mg | — |
| Background | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |
| Background | Vincristine | Small molecule | 0.4 mg/m2 | — |
| Background | Vincristine | Small molecule | 1.4 mg/m2 | — |
| Background | Vindesine | Small molecule | 3 mg/m2 | — |